Specialty drug tier placement is the mechanism commercial insurers, ACA Marketplace plans, and Medicare Part D plans use to shift a portion of the cost of the most expensive prescription drugs onto the patient through coinsurance instead of a flat-dollar copay. Most commercial and ACA formularies use a four-tier or five-tier structure: preferred generic, generic, preferred brand, non-preferred brand, and a specialty tier at the top, sometimes split into a lower and higher specialty tier. A drug typically lands on the specialty tier once its monthly ingredient cost crosses a threshold the insurer sets, commonly between $600 and $1,000 a month, though there is no single federal rule for commercial plans the way there is for Medicare Part D, where CMS sets a national $950 (2026) threshold. Specialty tier drugs are disproportionately biologics administered by injection or infusion, oral oncology drugs, and treatments for rare diseases like cystic fibrosis, multiple sclerosis, and hemophilia. Roughly 2% of prescriptions filled in the United States are specialty drugs, but they account for more than half of total US drug spending in 2026, which is the core reason insurers price-share them differently than a $10 generic copay.
Commercial employer plans and ACA Marketplace plans set specialty tier coinsurance most commonly between 30% and 40% of the drug's negotiated price in 2026, according to formulary designs reviewed by KFF, though the full published range across all plan types runs from 25% to 50%. Applied to real dollars, a mid-priced specialty biologic like Stelara or Enbrel listed near $7,000 to $14,000 a month produces coinsurance of $2,100 to $5,600 at 30%, or $2,800 to $7,400 at 40%, for a single fill. A lower-priced specialty drug at the roughly $1,000 monthly entry point produces $300 to $400 in coinsurance for the same fill. Bronze and Silver ACA Marketplace plans tend to sit at the higher end of that 30% to 40% band, since lower-premium plans typically shift more cost-sharing onto drug tiers, while Gold and Platinum plans and richer employer plans more often land near 30% or use a capped-dollar specialty tier instead. One critical distinction: the Inflation Reduction Act's Maximum Fair Price, which cuts Medicare's coinsurance base for 10 negotiated drugs including Stelara and Enbrel starting January 1, 2026, does not apply to commercial or ACA Marketplace claims. Those plans still calculate 30% to 40% coinsurance against the full, pre-negotiation list price.
Percentage coinsurance on the specialty tier is not arbitrary; it reflects a structural choice insurers make because a flat copay large enough to meaningfully offset a $10,000-a-month biologic would be unworkable for both the plan and the patient. Two features shape how much that coinsurance actually costs a patient in 2026. First, the 2026 ACA Marketplace annual out-of-pocket maximum, $10,600 for an individual and $21,200 for a family, caps total exposure once reached, after which covered drugs cost $0 for the rest of the plan year; most employer plans mirror or beat that federal ceiling. Second, manufacturer copay cards, legal for commercially insured patients (though barred for Medicare, Medicaid, TRICARE, and VA beneficiaries under federal anti-kickback law), can bring a specialty tier coinsurance bill down to $0 to $50 a month for eligible patients, but a growing number of plans use copay accumulator or maximizer programs that prevent that manufacturer assistance from counting toward the patient's deductible or out-of-pocket maximum, a billing distinction worth checking with your plan before assuming your coinsurance exposure is fully covered.
What Specialty Drug Tier Costs Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same specialty drug tier costs can cost many times more at a hospital than at your local pharmacy:
2026 Specialty Drug Tier Costs Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Employer-sponsored commercial plan, specialty tier (2026) | $300 - $4,800 per 30-day fill (30% to 40% coinsurance) | Applies after any separate drug deductible is met; roughly 155 million Americans had employer coverage in 2026 |
| ACA Marketplace plan, specialty tier (2026) | $300 - $4,800 per 30-day fill (30% to 40% coinsurance, higher on Bronze/Silver) | Counts toward the 2026 annual limit of $10,600 (individual) / $21,200 (family); varies by metal tier and insurer |
| Medicare Part D, specialty tier (2026) | $237.50 - $4,565.88 per 30-day fill (25% to 33% coinsurance) | Narrower band than commercial plans; IRA Maximum Fair Price lowers the coinsurance base for 10 negotiated drugs, commercial plans excluded |
| Medicaid | $1 - $8 per prescription, with prior authorization | Nominal copay set by state; check your state's Medicaid income limits for eligibility |
| Hospital outpatient infusion (medical benefit, buy-and-bill) | $6,000 - $20,000 per infusion facility charge | Billed under the medical benefit with a J-code rather than the pharmacy specialty tier; cost-sharing rules and coinsurance base differ from pharmacy claims |
Commercial and ACA figures reflect the published 30% to 40% specialty tier coinsurance range on drugs priced $1,000 to $12,000 a month in 2026. Medicare figures reflect the separate 25% to 33% Part D specialty tier band on the $950 (2026) threshold to $13,836 list-price range. Your actual cost depends on your specific plan's formulary and drug price.
Source: KFF Deductibles in ACA Marketplace Plans 2014-2026; CMS Specialty Tier Cost Threshold Methodology (CY 2026); CMS 2025 Marketplace Integrity and Affordability Final Rule; CMS Medicare Drug Price Negotiation Program 2026
Why Hospitals Charge So Much
Percentage coinsurance exists on the specialty tier because a flat-dollar copay large enough to meaningfully offset a $10,000-to-$14,000-a-month biologic would either bankrupt the plan's cost-sharing design or make the copay itself unaffordable for most patients. Setting cost-sharing as a percentage of the drug's actual price lets insurers share financial risk on high-cost drugs proportionally rather than absorbing a fixed loss on every fill. The tradeoff lands on the patient: open-ended dollar exposure per fill instead of a predictable copay, which is why the same 30% coinsurance can mean a $300 bill on one specialty drug and a $4,800 bill on another.
Buy-and-bill billing routes many infused specialty biologics through a patient's medical benefit rather than the pharmacy specialty tier entirely. Under buy-and-bill, a physician's office or hospital outpatient infusion center purchases the drug, administers it, and bills the insurer using a HCPCS J-code, similar to how any other in-office medical service is billed. Hospital outpatient infusion centers typically mark up the drug's acquisition cost with facility fees, nursing administration charges, and overhead, producing bills of $6,000 to $20,000 per infusion for a drug whose specialty pharmacy list price might run $2,000 to $5,000. Patients whose specialty drug is administered this way should ask whether an independent infusion center or their prescriber's office can administer the same drug at a lower facility rate, since the site of care can change the bill by thousands of dollars for an identical dose.
Copay accumulator and maximizer programs, used by roughly one-third of commercial plans in 2026 according to industry benefit-design surveys, change how manufacturer copay card dollars are treated even when the coinsurance percentage itself stays the same. An accumulator program lets the manufacturer copay card pay the coinsurance at the pharmacy counter but does not count that payment toward the patient's deductible or out-of-pocket maximum, meaning the patient's own dollars still have to satisfy those limits separately once the card's annual cap runs out. A maximizer program instead spreads the total value of a manufacturer copay card evenly across 12 months to keep the patient's out-of-pocket payment near $0 for as long as possible. Ask your plan's member services directly whether it uses an accumulator or maximizer program before assuming a manufacturer copay card fully protects you from specialty tier coinsurance for the full plan year.
Patient Assistance Programs
Specialty tier drugs are disproportionately biologics, oncology therapies, and rare-disease treatments, exactly the categories with the most established manufacturer and charity assistance infrastructure. Two distinct types of help exist and the rules differ by your insurance type: manufacturer copay cards (commercial insurance only, illegal for government-program patients) and independent 501(c)(3) charity foundations (available to commercial and Medicare patients alike, since they are not manufacturer-directed to specific patients).
Patient assistance programs for Specialty Drug Tier Costs| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Manufacturer Copay Card / Savings Program | $0 - $50/month for most commercially insured patients; illegal to use with Medicare, Medicaid, TRICARE, or VA coverage | needymeds.org |
| HealthWell Foundation | Disease-specific grants of roughly $1,000 - $10,000 a year toward coinsurance and copays; available to Medicare and commercial patients | healthwellfoundation.org |
| Patient Advocate Foundation Co-Pay Relief | Direct copay and coinsurance assistance for specific disease funds, including specialty biologics and oncology drugs | copays.org |
| PAN Foundation | Underinsured patient assistance funds covering coinsurance for over 70 disease-specific specialty drug categories | panfoundation.org |
| Manufacturer Patient Assistance Program (PAP) | Free specialty drug supply for uninsured patients at or below roughly 300% to 400% of the Federal Poverty Level | needymeds.org |
Manufacturer copay cards and savings coupons cannot legally be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). Independent 501(c)(3) charity foundations like HealthWell, Patient Advocate Foundation, and PAN Foundation are the correct alternative for government-insured patients because they are not manufacturer-directed to individual patients, an arrangement the HHS Office of Inspector General has recognized in advisory opinions. Commercially insured patients can generally use either type of assistance, subject to their plan's accumulator or maximizer program rules.
Source: HealthWell Foundation, Patient Advocate Foundation, PAN Foundation, NeedyMeds.org, HHS OIG Advisory Opinions on charitable patient assistance
Medicare Part D
Medicare Part D applies a narrower specialty tier coinsurance band than most commercial or ACA Marketplace plans. CMS sets a single national specialty tier ingredient-cost threshold, $950 for a 30-day equivalent supply in 2026, and caps plan-set coinsurance at 25% to 33% (versus the commercial 30% to 50% range), with the higher end permitted only if the plan waives some or all of the $615 (2026) standard deductible. On the same $950 to $13,836 price range used for commercial comparison, Medicare's coinsurance produces $237.50 to $4,565.88 for one fill, modestly lower than the $300 to $4,800 commercial range on the same dollar spread, largely because Medicare's ceiling tops out at 33% versus commercial plans that can run to 40% or higher.
Ten drugs carry an Inflation Reduction Act Maximum Fair Price effective January 1, 2026, including Stelara ($4,695, down from a $13,836 list price) and Enbrel ($2,355, down from $7,106), and Medicare Part D coinsurance for those drugs is calculated against the lower negotiated price. Commercial and ACA Marketplace plans do not receive that benefit; a commercially insured patient on Stelara still faces 30% to 40% coinsurance calculated against the full $13,836 list price unless a manufacturer copay card or charity grant offsets it, producing a dramatically different real-world cost than a Medicare beneficiary taking the identical drug.
Extra Help (the Low Income Subsidy) replaces Medicare's percentage coinsurance entirely for qualifying beneficiaries, dropping specialty tier cost-sharing to a flat $1.60 to $12.65 per fill in 2026 regardless of the plan's stated 25% to 33% rate. Commercial and ACA Marketplace plans have no direct equivalent; the closest analogs are the charity foundation grants and manufacturer copay cards described above, plus, for very low-income households, Medicaid eligibility, which brings nominal $1 to $8 copays. Anyone dual-eligible for Medicare and Medicaid should apply for Extra Help through Social Security at ssa.gov/extrahelp or 1-800-772-1213, since it stacks with, and often outperforms, both charity and manufacturer assistance for specialty tier drugs.
Common Specialty Drug Tier Costs Billing Errors
Specialty tier billing involves more variables than a standard copay, which creates several common and disputable errors. If your specialty tier bill does not match your plan's Summary of Benefits and Coverage or Explanation of Benefits, dispute it before paying:
- A copay accumulator program silently stripped manufacturer copay card credit from counting toward your deductible or annual out-of-pocket maximum, leaving you owing full coinsurance again later in the year
- A Medicare Part D claim charged the pre-negotiation list price coinsurance on an IRA-negotiated drug (Stelara, Enbrel, Imbruvica) instead of coinsurance based on the lower 2026 Maximum Fair Price
- A drug administered under the medical benefit (buy-and-bill, hospital outpatient infusion) was billed at the higher facility coinsurance rate when a specialty pharmacy fill of the same drug would have cost less
- Continued coinsurance charged after you already reached the 2026 annual out-of-pocket maximum ($10,600 individual / $21,200 family for ACA Marketplace plans, $2,100 for Medicare Part D)
- A drug placed on the specialty tier despite its monthly ingredient cost falling below your plan's stated specialty threshold after a price change or biosimilar entry
- A Medicare Extra Help enrollee charged the plan's standard 25% to 33% specialty tier coinsurance instead of the correct $1.60 to $12.65 flat copay cap
Frequently Asked Questions
What is a specialty drug tier?
A specialty drug tier is the highest cost-sharing category on a prescription drug formulary, reserved for the most expensive drugs, mostly biologics, oncology therapies, and rare-disease treatments. Commercial and ACA Marketplace plans typically call it Tier 4; Medicare Part D calls it Tier 5. Unlike lower tiers, which use flat-dollar copays, the specialty tier almost always uses coinsurance, a percentage of the drug's price, commonly 30% to 40% on commercial and ACA plans in 2026 and 25% to 33% on Medicare Part D.
What does 30% to 40% specialty tier coinsurance actually cost in dollars in 2026?
On a specialty drug priced around $1,000 a month, 30% coinsurance costs $300 and 40% costs $400 for one 30-day fill. On a higher-priced biologic listed near $12,000 a month, the same percentages produce $3,600 and $4,800 for a single fill. Your total exposure is capped by the 2026 annual out-of-pocket maximum, $10,600 for an individual and $21,200 for a family on ACA Marketplace plans; most employer plans mirror or beat that ceiling.
Is there a generic or biosimilar to avoid the specialty tier?
It depends on the specific drug. Specialty tier status is based on price, not brand status, so any drug, brand, generic, or biosimilar, priced above your plan's threshold qualifies. Humira (adalimumab) now has more than ten FDA-approved biosimilars, including Amjevita, Hyrimoz, and Cyltezo, some launched at list prices roughly 80% below Humira. Ask your prescriber and pharmacist whether a lower-priced biosimilar or generic exists for your specific specialty drug.
How do I apply for help paying specialty tier coinsurance?
Two paths exist depending on your insurance. Commercially insured patients should first check the manufacturer's copay card program, typically saving them $0 to $50 a month. Medicare, Medicaid, TRICARE, and VA patients cannot use manufacturer cards and should instead apply to an independent charity foundation like HealthWell Foundation (healthwellfoundation.org), Patient Advocate Foundation (copays.org), or PAN Foundation (panfoundation.org), all of which accept government-insured patients. Uninsured patients should apply directly to the drug manufacturer's patient assistance program for free medication.
Can I use a manufacturer copay card with my insurance for specialty tier coinsurance?
Yes, if you have commercial employer or ACA Marketplace insurance; manufacturer copay cards are legal for privately insured patients and can cut coinsurance to $0 to $50 a month. No, if you have Medicare, Medicaid, TRICARE, or VA coverage; federal anti-kickback law (42 U.S.C. Section 1320a-7b) bars manufacturer coupons for government-program beneficiaries. Independent charity foundations are the legal alternative for government-insured patients.
What if my insurance denies my specialty drug or places it on the highest tier?
Request a written denial notice, then file a formal internal appeal within your plan's stated window (commonly 30 days, or 72 hours if urgent). If the internal appeal fails, ACA Marketplace and most employer plans must offer an independent external review, and most states also require a step therapy override process when your prescriber documents medical necessity. Medicare Part D plans generally exclude specialty tier drugs from formulary tiering exceptions under federal rule.
Does the IRA negotiated Maximum Fair Price lower my specialty tier coinsurance?
Only if you have Medicare Part D and take one of the 10 drugs negotiated under the Inflation Reduction Act, including Stelara and Enbrel, effective January 1, 2026. Commercial employer plans and ACA Marketplace plans are not required to honor the Maximum Fair Price, so a commercially insured patient on the same drug still pays 30% to 40% coinsurance calculated against the full, pre-negotiation list price.
How is Medicare Part D's specialty tier different from my employer or ACA Marketplace plan's specialty tier?
Medicare Part D uses a single national ingredient-cost threshold ($950 in 2026) and caps coinsurance at 25% to 33%. Commercial and ACA Marketplace plans set their own thresholds, commonly $600 to $1,000 a month, and typically charge higher coinsurance, 30% to 40%, sometimes up to 50%. Medicare beneficiaries also get the IRA Maximum Fair Price on 10 negotiated drugs and Extra Help's flat copay option, neither of which is available on commercial or ACA plans.
